Status:
COMPLETED
Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
Lead Sponsor:
Stanford University
Conditions:
Rectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment an...
Detailed Description
Recent advances in computed tomography (CT) technology have made CT perfusion imaging feasible for the assessment of tumor perfusion in solid tumors of the abdomen. CT perfusion has shown promising re...
Eligibility Criteria
Inclusion
- Patients with suspected or biopsy-proven, locally advanced rectal cancer will be eligible for enrollment.
- Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant.
- No life expectancy restrictions.
- ECOG and Karnofsky Performance Status will not be employed.
- Patients with renal failure are ineligible for this study (GFR must be \> 60)
- Ability to understand and willingness to sign a written informed consent document.
Exclusion
- Patients who have undergone prior treatment for rectal cancer are ineligible for enrollment.
- No restrictions regarding use of other investigational agents.
- Patients with severe contrast allergy are ineligible.
- Patients who are pregnant or are trying to become pregnant are excluded from this study.
- Patients who are cancer survivors or HIV-positive will not be excluded.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2018
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01460641
Start Date
November 1 2011
End Date
July 1 2018
Last Update
September 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University, School of Medicine
Stanford, California, United States, 94305